Research

Hormonal

Dual or Triple Receptor Agonists (combining GLP-1, GIP, and/or Glucagon) offer superior reduction in liver fat and weight loss compared to selective GLP-1 receptor agonists alone.

Newer 'dual' and 'triple' hormone medications (like Tirzepatide or Efinopegdutide) appear to reduce liver fat and weight more effectively than older GLP-1 drugs alone. These are currently under investigation and may become the preferred treatment for MASLD, especially for those who need significant weight loss and liver fat reduction.

GoodSupportsHIGH confidence
Dual GLP-1 and GIPRA outperform single selective GLP-1RA in achieving better glycemic control and weight loss... balanced unimolecular triple agonists have been shown to have superior effects on body weight reduction, glycemic control, and hepatic steatosis regression.
Chencheng Xie et al. · World Journal of Hepatology · 2024

Why this rating

Supported by phase II/III trials and animal models, though human data for triple agonists is still emerging.

Source

Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges

Chencheng Xie et al. · World Journal of Hepatology · 2024

DOI 10.4254/wjh.v16.i5.731

narrative_reviewCited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →